Brought to you by 
Merck, Acumen R&D Alzheimer's therapeutics; terminated
01 May 2013
Executive Summary
Acumen Pharmaceuticals (memory-related disorders) will work with Merck & Co. on the research and development of therapeutics and vaccines to treat Alzheimer's disease and other memory disorders.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck, Acumen R&D Alzheimer's therapeutics; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice